Steve Grasso, Grasso Global CEO, joins 'Power Lunch' to discuss stock plays for three stocks.

The document notes that a phase 1 trial of two experimental Moderna RSV vaccines in infants aged five to eight months was ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Moderna Inc. closed $131.08 below its 52-week high ($170.47), which the company achieved on May 24th.

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

Short interest for healthcare stocks in S&P 500 rose in November vs. October, while Moderna continued to be the most shorted ...

Moderna Inc. closed $129.71 short of its 52-week high ($170.47), which the company achieved on May 24th.

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...